YAP/TAZ pathway has been linked to multi-drug resistance among a variety of cancers, and is considered of interest in HNSCCs due to common genomic alterations affecting YAP/TAZ activity and regulation, as well as their characteristic fibrotic TME [178]. Here, YAP1 is linked to cancer.